Sepsis Diagnostic Market by Testing Type, Technology, Product, Method, Pathogen, End-user

Description

List of Tables

[196 Pages Report] The Sepsis Diagnostic Market size was estimated at USD 556.86 million in 2023 and expected to reach USD 611.80 million in 2024, at a CAGR 9.98% to reach USD 1,084.17 million by 2030.

Sepsis diagnostics refers to the variety of procedures and tests used to identify and confirm the presence of sepsis in patients. Sepsis is a condition that arises from the body's reaction to an infection that causes injury to its tissues and organs; thus, sepsis diagnostics are essential for the timely and accurate detection of sepsis, leading to immediate and appropriate treatment interventions. There is an increasing need for sepsis diagnostics, as they are critical in saving lives, preventing disease progression, reducing healthcare costs, and enhancing the quality of life for patients impacted by sepsis. The growing number of sepsis cases globally due to rising infection rates, aging populations, and higher susceptibility in individuals with chronic diseases has led to an increasing need for efficient diagnostic methods. Improved healthcare infrastructure, particularly in developing countries, along with better healthcare policies and increased healthcare spending, supports the growth of the sepsis diagnostic market. However, the lack of awareness and understanding of sepsis in several underdeveloped regions limits the need for diagnostic solutions. Nevertheless, advances in technology that offer the potential to reduce diagnosis time and improve patient outcomes are expected to create opportunities for the adoption of sepsis diagnostics solutions.

KEY MARKET STATISTICS
Base Year [2023]	USD 556.86 million
Estimated Year [2024]	USD 611.80 million
Forecast Year [2030]	USD 1,084.17 million
CAGR (%)	9.98%

Regional Insights

In the Americas, particularly in North America, the sepsis diagnostics market is witnessing significant growth, growing healthcare facilities, heightened awareness about sepsis, and substantial investment in research and diagnostic technologies. South America is seeing improvements in healthcare access and an increasing emphasis on early diagnosis and treatment, driving the need for sepsis diagnostics. Asia-Pacific region represents an emerging sepsis diagnostics market, propelled by its large population, elevating healthcare expenditure, and growing awareness of sepsis as a critical health issue. Countries in the Asia-Pacific are benefiting from governmental healthcare reforms and investments in healthcare infrastructure, causing a significant adoption of advanced sepsis diagnostics solutions. The Europe, Middle East, and Africa region presents a varied landscape for the sepsis diagnostics market. Europe noticed strong growth driven by well-established healthcare systems, high healthcare spending, and stringent regulatory standards promoting the adoption of advanced diagnostics.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Sepsis Diagnostic Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Increasing Incidence and Prevalence of Sepsis
- Growing Occurrence of Hospital Derived Infections
- Development of Technology Advanced Diagnostic Solutions

Market Restraints
- Capital Intensive Automated Diagnostic Services and Dearth of Reimbursement Situations

Market Opportunities
- Emerging Development of Rapid Diagnostics Globally
- Development of Novel Biomarkers for Sepsis Diagnostics

Market Challenges
- Lack of Awareness and Standard Protocols for the Procedure

Market Segmentation Analysis
- Testing Type: Increasing usage of PoC testing solutions for sepsis diagnostics
- End-user: Emerging use of advanced sepsis diagnostics solutions in pathology and reference laboratories

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Sepsis Diagnostic Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Sepsis Diagnostic Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Unveiling of FDA-Authorized AI Tool by Prenosis, Inc.

Prenosis, Inc. achieves a monumental milestone with the FDA's marketing authorization of the Sepsis ImmunoScore, marking the debut of an AI-driven diagnostic tool for sepsis. With this FDA authorization, Prenosis underscores its dedication to transforming acute care through precision medicine, heralding a new era in personalized healthcare solutions driven by AI diagnostics. [Published On: 2024-04-03]

Innovative AI-Powered Early Detection of Sepsis by Presymptom Health Secures GBP 1.5 Million in Funding

Presymptom Health secured GBP 1.5 million in a combination of equity and grant funding, reflecting the potential of its AI and machine learning technologies to revolutionize early infection detection. Leveraging vast biobank data, Presymptom Health's advanced analytics can identify signs of infections and sepsis significantly earlier than traditional methods, potentially days before clinical symptoms become apparent. This funding round, featuring contributions from UKI2S, Ploughshare, and MedTechToMarket along with Innovate UK grants, underscores AI's significant advances and the promise in healthcare, especially for conditions including sepsis that need swift intervention. [Published On: 2024-03-21]

Cytovale's Strategic Advancement with USD 84 Million Series C Funding

Medical technology firm Cytovale made a stride in sepsis diagnosis with its innovative test, IntelliSep, through an USD 84 million Series C funding round. This funding aims to tackle the pressing issue of delayed sepsis diagnosis, which incurs an annual cost of USD 62 billion nationwide. [Published On: 2023-11-15]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Sepsis Diagnostic Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Sepsis Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alifax S.r.l., Beckman Coulter, Inc., Becton, Dickinson and Company, bioMerieux SA, Boditech Med Inc., Bruker Corporation, CytoSorbents Corporation, DiaSorin S.p.A., EKF Diagnostics, F. Hoffmann-La Roche AG, Immunexpress Inc., Koninklijke Philips N.V., McKesson Corporation, Nanomix Inc., Oracle Corporation, Response Biomedical Corporation, Seegene Inc., Siemens Healthineers, T2 Biosystems, Thermo Fisher Scientific, Inc., and Wolters Kluwer N.V..

Market Segmentation & Coverage

This research report categorizes the Sepsis Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

Testing Type
- Laboratory Testing
- PoC Testing

Technology
- Flow Cytometry
- Immunoassays
- Microbiology
- Molecular Diagnostics

Product
- Assay Kits and Reagents
- Blood Culture Media
- Instruments
- Software

Method
- Automated Diagnostics
- Conventional Diagnostics

Pathogen
- Bacterial Sepsis
  - Gram-Negative Bacteria
  - Gram-Positive Bacteria

Fungal Sepsis

End-user
- Hospitals
- Pathology & Reference Laboratories
- Research Laboratories & Academic Institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-A339DAEFABA1

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing Incidence and Prevalence of Sepsis
  - 5.1.1.2. Growing Occurrence of Hospital Derived Infections
  - 5.1.1.3. Development of Technology Advanced Diagnostic Solutions
- 5.1.2. Restraints
  - 5.1.2.1. Capital Intensive Automated Diagnostic Services and Dearth of Reimbursement Situations
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging Development of Rapid Diagnostics Globally
  - 5.1.3.2. Development of Novel Biomarkers for Sepsis Diagnostics
- 5.1.4. Challenges
  - 5.1.4.1. Lack of Awareness and Standard Protocols for the Procedure
5.2. Market Segmentation Analysis
- 5.2.1. Testing Type: Increasing usage of PoC testing solutions for sepsis diagnostics
- 5.2.2. End-user: Emerging use of advanced sepsis diagnostics solutions in pathology and reference laboratories
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Sepsis Diagnostic Market, by Testing Type

6.1. Introduction
6.2. Laboratory Testing
6.3. PoC Testing

7. Sepsis Diagnostic Market, by Technology

7.1. Introduction
7.2. Flow Cytometry
7.3. Immunoassays
7.4. Microbiology
7.5. Molecular Diagnostics

8. Sepsis Diagnostic Market, by Product

8.1. Introduction
8.2. Assay Kits and Reagents
8.3. Blood Culture Media
8.4. Instruments
8.5. Software

9. Sepsis Diagnostic Market, by Method

9.1. Introduction
9.2. Automated Diagnostics
9.3. Conventional Diagnostics

10. Sepsis Diagnostic Market, by Pathogen

10.1. Introduction
10.2. Bacterial Sepsis
10.3. Fungal Sepsis

11. Sepsis Diagnostic Market, by End-user

11.1. Introduction
11.2. Hospitals
11.3. Pathology & Reference Laboratories
11.4. Research Laboratories & Academic Institutes

12. Americas Sepsis Diagnostic Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Sepsis Diagnostic Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Sepsis Diagnostic Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
- 15.3.1. Unveiling of FDA-Authorized AI Tool by Prenosis, Inc.
- 15.3.2. Innovative AI-Powered Early Detection of Sepsis by Presymptom Health Secures GBP 1.5 Million in Funding
- 15.3.3. Cytovale's Strategic Advancement with USD 84 Million Series C Funding
15.4. Strategy Analysis & Recommendation

16. Competitive Portfolio

16.1. Key Company Profiles
16.2. Key Product Portfolio